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60 % of exposure compared with drug intake either 30 min 
before, 30 min after (fed), or 2 h after a high-fat meal. 
Similar food effect was observed (study 3) when ibrutinib 
was given 30 min before meal. In CLL patients (study 2), 
the Cmax and AUC under fasting conditions were 43 and 
61 %, respectively, relative to fed conditions. When admin-
istered once-daily in uncontrolled food-intake conditions 
(≥30 min before or 2 h after), exposures were slightly 
(≈30 %) lower than in fed condition. When corrected for 
repeated dosing, pharmacokinetic parameters in healthy 
participants and patients were comparable. Ibrutinib was 
generally well tolerated in all settings studied.
Conclusions Ibrutinib administered in fasted condition 
reduces exposure to approximately 60 % as compared with 
dosing in proximity to food-intake, regardless of timing/
type of meal. Because repeated drug intake in fasted con-
dition is unlikely, no food restrictions may be needed to 
administer ibrutinib.
Keywords Chronic lymphocytic leukemia · Food effect · 
Ibrutinib · Pharmacokinetics · Tyrosine kinase inhibitor
Introduction
Ibrutinib (Imbruvica®) was recently approved in the USA 
and European Union for the treatment of previously treated 
chronic lymphocytic leukemia (CLL) [1] and mantle cell 
lymphoma (MCL) [2] in patients who have had at least one 
prior therapy. The most common type of leukemia in the 
Western world is CLL and has a mean onset between 65 
and 75 years of age. It is characterized by an accumula-
tion of mature B cells in the blood, lymph nodes, and bone 
marrow [3]. There were an estimated 15,680 new cases of 
CLL among the 69,740 newly diagnosed non-Hodgkin’s 
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lymphoma cases in the USA in 2013 [4]. Another form of 
non-Hodgkin’s lymphoma is MCL, which is difficult to 
treat and leaves patients with a poor prognosis [2, 5]. Cyto-
toxic chemotherapeutic agents are often used to treat B cell 
malignancies, and although survival may be improved, the 
disease is not curative [6]. Patients must be able to toler-
ate the side effects and toxicities associated with these 
agents and of particular concern, myelotoxic effects, which 
increases the risk of opportunistic infections. With exist-
ing frontline treatments involving multi-agent chemoim-
munotherapy regimens, disease resistance to treatment is 
common in patients with relapse. A phase III study (RES-
ONATE) in previously treated CLL patients demonstrated 
ibrutinib treatment reduced the risk of progression or death 
by 78 % compared to the CD20-directed monoclonal anti-
body, ofatumumab [7]. The safety profile was acceptable 
with no increase in the risk of grade 3/4 adverse events 
(AEs) with ibrutinib. Furthermore, despite advances, most 
patients with CLL and MCL die of their disease [2, 8, 9]. 
Therefore, novel therapies are needed for improved medi-
cal treatment for these malignant diseases.
Many factors contribute to the viability of B cells and 
their development, proliferation, and survival, includ-
ing B-cell receptor (BCR) activation and signaling [10]. 
The BCR signaling is a key factor in the survival of B 
cell malignancies [11–13]. Although the exact mechanism 
by which BCR regulates B cell activity is unknown, BCR 
activation is mediated via a cascade of enzymatic activ-
ity, among which is an essential kinase enzyme, Bruton’s 
tyrosine kinase (BTK) [14, 15]. Bruton’s tyrosine kinase 
is expressed in all hematopoietic cells, with the exception 
of T lymphocytes and natural killer cells [16]. Dysfunc-
tional BTK, due to mutations, leads to an inherited disease, 
X-linked agammaglobulinemia, in which patients lack 
peripheral mature B cells, have increased serum immuno-
globulin, and are more susceptible to infection [16, 17]. 
Therefore, it is reasonable to target BTK to inhibit survival 
and proliferation of malignant B cells.
Preclinical studies have demonstrated that ibrutinib 
inhibits several processes, including survival, proliferation, 
adhesion, and tumor cell migration [18–20]. Inhibition of 
BTK is a novel mechanism to treat non-Hodgkin’s lym-
phoma, and ibrutinib does this by forming an irreversible 
covalent bond with BTK at the Cys 481 site. In early stud-
ies, ibrutinib as a single agent demonstrated high response 
rates and durable efficacy in previously treated B cell 
malignancies [1, 2, 21].
As ibrutinib is orally administered, it is important to 
determine the relative bioavailability in relation to meal 
consumption. Typical for first-in-human studies in a 
patient setting, and because the absence or presence of a 
food effect had not been confirmed in preclinical studies, 
it was deemed advisable to avoid both fully fasted and fed 
conditions in studies supporting the early clinical develop-
ment of ibrutinib [22].
The primary objective of the current analysis was to 
assess the effect of food on the pharmacokinetics (PK) of 
ibrutinib at 420 mg, the therapeutic dose for CLL, as well 
as to investigate the effects of food timing and type of 
meal. Secondary objectives included determining the PK 
of ibrutinib metabolite PCI-45227 and assessing the safety 
and tolerability of ibrutinib administered in single doses up 
to 560 mg.
Materials and methods
Study design and treatment
Two studies were designed to evaluate the effect of a 
high-fat meal on ibrutinib exposure. A third, explora-
tory, study tested the effect of a standard breakfast. Study 
1 (NCT01820936) was a randomized, open-label, single-
center, single-dose, four-way crossover study in 44 healthy 
participants. Study 2 (NCT01105247) was a two-center, 
randomized (fasted vs. fed), repeat-dose crossover substudy 
in 16 patients with previously treated CLL who were able 
to roll over to a long-term extension study after 6 months of 
treatment (NCT01109069). Study 3 (NCT01866033) was 
an open-label, single-center, single-dose, sequential study 
in eight healthy participants.
Healthy participants received a single, oral ibrutinib 
420 mg (study 1) or 560 mg dose (study 3) on day 1 of 
each treatment period; patients with previously treated CLL 
(study 2) received ibrutinib 420 mg daily. For all treatment 
arms, participants were confined in the study center during 
PK blood sample collection (72 h: studies 1 and 3; 24 h: 
study 2). In studies 1 and 3, there was a washout period 
of 7 days between dosing in subsequent periods. In study 
2, as in all other ibrutinib studies in patients, investigators 
instructed patients to take the drug, per protocol, at least 
30 min before or 2 h after a meal on nonsampling days. 
Patients were allowed to take their concomitant medica-
tions on all days. In addition to the formal (fasted/fed) PK 
evaluations in study 2 under repeat-dosing conditions, an 
uncontrolled food timing evaluation was performed on day 
1 under single-dose condition. As the day 1 PK evaluation 
was uncontrolled, no formal statistical comparisons were 
performed between single-dose and repeat-dose conditions.
All treatment regimens started with an overnight fast 
(≥10 h), followed by a controlled combination of ibrutinib 
and food-intake. All studies explored a controlled fasting 
state (Treatment A). Study 1 explored dosing/food-intake 
regimens, including ibrutinib 30 min before a meal (treat-
ment B); 30 min after completing a meal (fed, treatment 
D); and 2 h after a meal (treatment C). Study 2 utilized 
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fasting state (treatment A) and fed state (treatment D) and 
also evaluated PK on day 1 where patients were allowed 
to take ibrutinib at uncontrolled food-intake conditions (at 
least 30 min before or 2 h after meal; treatment X). Study 
3 utilized treatment A and treatment B (30 min before 
meal). Treatment descriptions are shown in Supplementary 
Table 1 and treatment sequences in Fig. 1a–c.
In studies 1 and 2, the test meal was composed of 800–
1000 calories, approximately 50 % of which was derived 
from fat and was to be consumed in 30 min. In study 3, 
during treatment B, ibrutinib was given 30 min after a sug-
ary drink; participants then consumed a standard fat meal 
within 20 min. In study 1, water was allowed 2 h after 
ibrutinib administration. In studies 2 and 3, water was 
allowed up to 1 h before and after ibrutinib administration, 
and 1 h before and 2 h after administration, respectively. In 
all studies, healthy participants and patients took ibrutinib 
with 240 mL of water and a meal was provided approxi-
mately 4 h after ibrutinib administration.
Eligibility
In studies 1 and 3, participants included healthy men and 
women 18–55 years of age who had a body mass index 
(BMI) between 18 and 30 kg/m2 (inclusive) and weight 
≥50 kg.
Fig. 1  Treatment sequence. a 
Study 1: healthy participants 
receiving single-dose oral 
ibrutinib, b study 2: patients 
with previously treated chronic 
lymphocytic leukemia receiving 
repeat-dose oral ibrutinib, c 
study 3: healthy participants 
receiving single-dose oral 
ibrutinib. PK pharmacokinet-
ics. Treatment A = Ibrutinib 
orally administered after fasting 
for ≥10 and 4 h before the 
next food-intake. Treatment 
B = Ibrutinib orally adminis-
tered after fasting for ≥10 h 
and 30 min before a meal. 
Treatment C = Ibrutinib orally 
administered 2 h after a meal. 
Treatment D = Ibrutinib orally 
administered 30 min after 
completing a meal. Treatment 
X = Ibrutinib orally adminis-
tered at least 30 min before or at 
least 2 h after a meal. aHealthy 
participants receiving single-
dose study drug. bPatients with 
previously treated chronic 
lymphocytic leukemia receiving 
repeat-dose study drug
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Participants were excluded for prior or current illness 
that could interfere with the interpretation of the results; 
any clinically significant abnormal findings in laboratory 
values for hematology or chemistry, urinalysis, physical 
examination, or vital signs; use of prescription or nonpre-
scription medications including nonsteroidal anti-inflam-
matory drugs ≤7 days prior to screening; use of herbal sup-
plements 30 days prior to the study or vitamins ≤14 days 
prior to administration of the first dose of the study drug 
(acetaminophen or hormonal replacement therapy were 
permitted); history of drug or alcohol abuse; known allergy 
to the study drug or excipients of the formulation; recent 
blood donation or loss of blood volume of ≥500 mL; posi-
tive test for hepatitis B or C or human immunodeficiency 
virus infection; use of nicotine in the past 2 months; or 
planned surgery. Eligibility criteria for study 2 are previ-
ously published [1]. The key inclusion criteria included a 
diagnosis of relapsed or refractory CLL or small lympho-
cytic lymphoma, as defined according to the International 
Workshop on CLL and World Health Organization classifi-
cations and a need for treatment.
Pharmacokinetic assessments
Plasma and urine concentrations of ibrutinib and its metab-
olite PCI-45227 were measured using liquid chromatog-
raphy with tandem mass spectrometry. The ibrutinib PK 
parameters across all studies included maximum observed 
plasma concentration (Cmax), time to Cmax (tmax), area under 
the plasma concentration–time curve (AUC) from time 0 to 
the time of last quantifiable concentration (AUClast), AUC 
from 0 to 24 h (AUC0–24h), and elimination half-life (t1/2).
Safety assessments
In studies 1 and 3, clinical laboratory tests including hema-
tology, platelet function assay (PFA-100), serum chemistry, 
urinalysis, electrocardiogram (ECG), physical examina-
tion, and vital signs were assessed. A follow-up visit was 
completed at 10 ± 2 days after the last dose to evaluate 
lymphocyte count and any additional AEs. Study 2 safety 
assessments have previously been described [1].
Sample collection
In studies 1 and 3, blood samples (2 mL) for PK evaluation 
of ibrutinib and its metabolite PCI-45227 were collected at 
predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 
and 72 h postdose during each treatment period. In study 
2, blood samples (2 mL) were collected at predose and 0.5, 
1, 2, 4, 6, and 24 h after ibrutinib administration, and at the 
same time points for the formal food effect comparison at 
steady state on days 8 and 15.
Statistical analyses
For PK parameters, linear mixed-effect models were 
applied in log-transformed PK parameters (Cmax, AUClast, 
and AUC0–24h) with treatment, period, and treatment 
sequence as fixed effects and participants as random effect. 
Geometric mean ratios (GMRs) between tests and refer-
ences of Cmax and AUClast and the corresponding 90 % 
confidence intervals (CIs) were constructed following 
back-transformation. Descriptive statistics were used to 
describe PK parameters. Non-compartmental analysis with 
WinNonlin Professional software version 5.2.1 (Pharsight 
Corp, Mountain View, CA, USA) was used to calculate PK 
parameters for ibrutinib and metabolite PCI-45227. Con-
centrations below the lower level of quantifiable concentra-
tion were treated as zero in the summary statistics.
In studies 1 and 3, descriptive statistics were used for 
age, BMI, weight, and height in participants who received 
≥1 dose of study drug. All participants who received ≥1 
dose of study drug were included in the safety analyses. All 
AEs were recorded and followed throughout the study and 
follow-up.
In study 1, a sample size of 44 participants was planned 
based on statistical estimation to enable the study to pro-
vide an estimate on the magnitude of food effect with pre-
cision close to the limit of 80–125 %.
Results
Participant’s disposition and baseline characteristics
Of the 44 participants (38 men) enrolled in study 1 
(Table 1), one participant prematurely discontinued (with-
drew consent) after period 1 and was not included in the 
PK analysis. The median (range) age was 39 (24–55) years. 
Baseline demographics were comparable across treatment 
groups. In study 2, all 16 patients (14 men) with previously 
treated CLL completed the study. Patients were 51–80 
(median 62) years of age. Additional baseline characteris-
tics for patients in study 2 have previously been reported 
[1]. In study 3, all eight participants (3 men) completed the 
study (Table 1).
Intra-study pharmacokinetic results
Ibrutinib concentration time curves and cross-study com-
parisons of Cmax and AUC in fed and fasting conditions are 
shown in Fig. 2a, b, and Table 2 lists PK parameters across 
the studies. In study 1, ibrutinib Cmax and AUC GMR in 
the fed condition (treatment D, 30 min after a meal) were 
3.15 and 1.86, respectively, compared with the fasting state 
(treatment A). When timing of ibrutinib changed from the 
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fed condition to 2 h after a meal (treatment C), Cmax and 
AUC GMR were 3.85 and 1.78, respectively. In studies 
1 and 2, under fed conditions (treatment D), the ibrutinib 
AUClast GMRs were similar (1.86 vs. 1.65, respectively), 
while the ibrutinib Cmax GMR was slightly higher in 
study 1 than in study 2 (3.15 vs. 2.24). In study 1, expo-
sure measured as AUClast was lower in the fasted condi-
tion (treatment A), relative to exposure with dosing within 
30 min to 2 h of food-intake. The AUClast in the fasted 
state (treatment A) was 63.2 % compared with dosing 
30 min before a meal (treatment B), 55.5 % versus dosing 
2 h after a meal (treatment C), and 56.2 % versus dosing 
30 min after a meal (treatment D). The Cmax and AUC val-
ues for uncontrolled food timing on day 1 (≥30 min before 
or 2 h after; treatment X) in study 2 were intermediate to 
those of fed (treatment D) and fasted conditions (treatment 
A). The Cmax and AUC in fasting conditions were 43 and 
61 %, respectively, relative to fed conditions. In study 3, 
Cmax GMR was 3.52 and AUClast GMR was 2.23, for dos-
ing in the pre-fed condition (treatment B) as compared to 
the fasted condition. 
In studies 1 and 2, under fasted conditions, ibrutinib was 
rapidly absorbed after oral administration with a median 
tmax of 2 h while the median tmax under fed conditions was 
4 h. In line with the variability in exposures, a wide range 
of apparent clearance values was observed for both study 1 
and 2 (Fig. 3).
In study 1, compared with the fasted condition, PCI-
45227 concentrations were higher when ibrutinib was 
administered with a meal, and Cmax was highest when ibru-
tinib was given 30 min after a meal. Compared with the 
fasted condition, PCI-45227 mean Cmax was 1.7–2.9 times 
higher, and AUC was 1.4–2.3 times higher when dosed with 
a meal. Half-life remained similar across all treatments. 
A trend in metabolite-to-parent ratios could not be identi-
fied. Similarly in study 3, PCI-45227 exposure increased 
(approximately 1.6-fold) when ibrutinib was administered 
with food compared with the fasting condition. In stud-
ies 1 and 2, the PCI-45227 mean tmax was achieved in 4 h 
under fed conditions (treatment D) compared with 2 h in 
the fasted condition (treatment A).
Safety
Across all studies, there were no serious treatment-emer-
gent adverse events (TEAEs) related to ibrutinib. During 
the food effect evaluation, no patients in study 2 discontin-
ued treatment or required dose reduction due to a TEAE. 
There were no deaths during food effect evaluation.
In study 1 (single-dose, 420 mg ibrutinib), 13 (29.5 %) 
participants reported ≥1 TEAE (Table 3). All TEAEs were 
of grade 1 severity except for one participant who experi-
enced a grade 2 TEAE of viral syndrome. The most com-
mon TEAEs (n = ≥3) were diarrhea and headache [3/44 
(6.8 %), each]. Overall, there were no clinically significant 
observations in ECG, vital signs, or laboratory values (data 
not shown).
In study 2 (repeat-dose, 420 mg ibrutinib), during the 
food effect evaluation, all 16 patients experienced at least 1 
TEAE. A total of 18.8 % of patients had experienced grade 
≥3 that was considered related. The most frequent serious 
adverse event (SAE) in this heavily pretreated population 
was pneumonia. In study 3 (single-dose, 560 mg ibrutinib), 
two participants experienced TEAEs, including lighthead-
edness (n = 2), abdominal cramps (n = 2), and diarrhea 
(n = 1). These events were grade 1 in severity except for 
grade 2 abdominal cramps in one participant. Overall, there 
were no clinically significant observations in ECG, vital 
signs, or laboratory values (data not shown).
Discussion
These three studies sought to understand the impact of food 
on the relative bioavailability of oral ibrutinib (420 and 
560 mg) by evaluating the effect of three meal times and a 
fasting state. Food can change the bioavailability of a drug 
and thus can have clinical consequences. Specifically, food 
Table 1  Baseline characteristics of participants from studies 1 and 3
BMI body mass index, SD standard deviation
a
 Healthy participants receiving single-dose study drug
Demographic/characteristics Study 1 (na = 44) Study 3 (na = 8)
Age (years)
 Mean (SD) 38.5 (9.7) 46.4 (8.1)
 Median (range) 39.0 (24–55) 48.5 (34–55)
Men, n (%) 38 (86.4) 3 (37.5)
Race, n (%)
 White 12 (27.3) 8 (100)
 Asian 1 (2.3) 0
 Black or African American 29 (65.9) 0
 Multiple 2 (4.5) 0
Ethnicity, n (%)
 Hispanic or Latino 9 (20.5) 0
 Not Hispanic or Latino 35 (79.5) 8 (100)
Weight (kg)
 Mean (SD) 79.3 (10.7) 70.0 (13.2)
 Median (range) 80.1 (54.7–96.9) 69.7 (50.7–90.6)
Height (cm)
 Mean (SD) 174 (9.0) 172 (11.3)
 Median (range) 174 (154–196) 170 (160–189)
BMI (kg/m2)
 Mean (SD) 26.2 (2.5) 23.5 (2.7)
 Median (range) 26.9 (19.7–29.4) 23.0 (19.6–27.4)
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effects on bioavailability are greatest when a drug is admin-
istered within a short time period in relation to a meal. 
Some of the ways food affects bioavailability are through 
delayed gastric emptying, changes in gastrointestinal pH, 
or improved solubility. Another effect of food-intake is 
increased splanchnic blood flow. As patient instructions for 
clinical studies suggest ibrutinib to be taken at least 30 min 
before or 2 h after a meal, these scenarios were used to 
determine the relationship between ibrutinib and food. To 
properly evaluate this relationship, single-dose ibrutinib 
was analyzed under various timing sequences in relation 
to food. The results of these analyses were then compared 
with the PK of repeat-dose ibrutinib administration in clini-
cal patients with refractory CLL.
In study 1, race was primarily represented by black or 
African American populations, while in studies 2 and 3, 
the population was primarily white. The median age and 
weight of patients with CLL in study 2 were greater than 
that of healthy participants. However, population PK analy-
sis across three patient studies did not suggest an effect of 
these covariates on ibrutinib clearance [23]. An exploratory 
comparison between the white and black participants in 
study 1 did not suggest an effect of race (data not shown). 
Therefore, results could be comparable between studies.
Administration of ibrutinib in a fasted condition resulted 
in approximately 60 % of plasma exposure (AUClast) as 
compared with administration either 30 min before or 2 h 
after a meal. Because ibrutinib is a high-clearance drug, 
known to be mediated by CYP3A and limited by blood 
flow, the observed food effect is most likely caused by 
an increase in intestinal blood flow rather than increased 
absorption. The higher blood flow increases the passage 
from the intestine into the portal circulation, thus decreas-
ing the first-pass effect caused by intestinal CYP3A. The 
higher the intestinal CYP3A activity, the more pronounced 
the blood flow-mediated effect of food on first-pass 
Fig. 2  a Log-linear time versus 
concentration curve in plasma 
following 420 and 560 mg 
oral ibrutinib administration 
with various meal and meal-
time adjustments in healthy 
participants and patients with 
chronic lymphocytic leukemia. 
b Cross-study comparisons 
of Cmax and AUC in fed and 
fasting conditions. AUC area 
under the plasma concentra-
tion–time curve, Cmax maximum 
observed plasma concentra-
tion. Treatment A = Ibrutinib 
orally administered after fasting 
for ≥10 and 4 h before the 
next food-intake. Treatment 
B = Ibrutinib orally adminis-
tered after fasting for ≥10 h 
and 30 min before starting a 
meal. Treatment C = Ibrutinib 
orally administered 2 h after a 
meal. Treatment D = Ibrutinib 
orally administered 30 min after 
completing a meal. Treatment 
X = Ibrutinib orally adminis-
tered at least 30 min before or 
at least 2 h after a meal. aStudy 
2 treatments A and D dose 
obtained at steady state, all 
others after single-dose. bDose 
normalized to a 420 mg dose
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metabolism. The result of this effect can be observed in the 
potential positive trend when comparing the food effect in 
individual participants with baseline ibrutinib clearance 
(Fig. 3).
Elimination half-life appeared shorter (approximately 
5 h) when ibrutinib was administered after the meal com-
pared with dosing under fully fasted or 30 min before meal 
conditions (9–13 h). It can be speculated that flip-flop 
kinetics occur here: when the dose of drug follows food-
intake by either 30 min or 2 h after drug intake, delayed 
absorption may be the result. Under fasted conditions, ibru-
tinib concentrations were much more variable. A second-
ary peak was observed during the distribution phase, which 
was not observed when given with food. The second peak 
coincides with lunch time, and this meal may trigger bile 
secretion from the gall bladder, accelerating solubility of 
the drug already in the gastrointestinal lumen. The expo-
sure to metabolite PCI-45227 was also higher in the fed 
state than fasted state for both Cmax and AUC. Half-life, 
however, was similar under all conditions. There was no 
definitive trend for metabolite–parent ratio.
Safety results from the food effect evaluation in study 2 
(with CLL patients) were comparable to those of the larger 
study population [1]. Across studies 1 and 3 in healthy par-
ticipants, the safety profile of ibrutinib was similar with all 
treatments. In addition, there were no clinically important 
treatment-emergent changes or adverse trends in hema-
tology, clinical chemistry, urinalysis, ECG, or vital signs. 
Overall, ibrutinib had an acceptable safety profile.
As ibrutinib is a novel therapy in CLL and MCL treat-
ment, with a unique mechanism of action, it is important to 
continue investigating this therapy.
In conclusion, single oral doses of ibrutinib 420 and 
560 mg and repeat doses of 420 mg had acceptable safety 
profiles in healthy participants and patients with previously 
Fig. 3  Correlation between clearance rate of ibrutinib and food effect 
on AUC
Table 3  Treatment-emergent adverse events in ≥15 % of population
Data shown as n (%)
TEAE treatment-emergent adverse event
a
 Healthy participants receiving single-dose study drug
b
 Patients with previously treated chronic lymphocytic leukemia receiving repeat-dose study drug
Adverse event Study 1 (na = 44) Study 2 (nb = 16) Study 3 (na = 8)
Number of healthy participants/patients with TEAEs 13 (29.5) 16 (100.0) 3 (37.5)
 Abdominal pain 1 (2.3) 0 3 (37.5)
 Diarrhea 3 (6.8) 11 (68.8) 3 (37.5)
 Vomiting 0 4 (25.0) 1 (12.5)
 Dizziness 1 (2.3) 0 2 (25.0)
 Headache 3 (6.8) 4 (25.0) 1 (12.5)
 Hyperventilation 0 0 1 (12.5)
 Arthralgia 0 5 (31.3) 0
 Contusion 0 4 (25.0) 0
 Epistaxis 0 4 (25.0) 0
 Fatigue 0 4 (25.0) 0
 Pneumonia 0 4 (25.0) 0
 Upper respiratory tract infection 0 4 (25.0) 0
 Chills 0 3 (18.8) 0
 Increased tendency to bruise 0 3 (18.8) 0
 Muscle spasms 0 3 (18.8) 0
 Pain in extremity 0 3 (18.8) 0
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treated CLL. After administration of ibrutinib in fully fasted 
conditions, plasma exposure (AUC) is about 60 % of what 
is observed when dosing was in proximity to a meal (from 
30 min before to 2 h after food-intake). Considering the 
favorable safety profile and the unlikeliness of repeated intake 
in fasted conditions, no food restrictions are needed to admin-
ister ibrutinib. Thus, ibrutinib is registered in the USA and 
European Union for administration regardless of food intake.
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